Citations

Clear

55 citation(s) found for "Sengupta, S".

Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
Martín, Miguel , Esteva, Francisco J. , Alba, Emilio , Khandheria, Bijoy K. , Pérez-Isla, Leopoldo, García-Sáenz, José Á. , Márquez, Antonia, Sengupta, Partho P. , Zamorano, José Luis , Isla, Leopoldo Pérez de , García-Sáenz, José A , Martin, Miguel , Alba, Emilio

Mayo Clinic

The Oncologist | January 16, 2009 | Volume: 14 | Issue: 1 | Pages: 1-11

10.1634/theoncologist.2008-0137 | PMID 19147689 Get It

Learning Objectives Analyze the clinical trial data for the treatment of breast cancer. Evaluate the risk of cardiotoxicity associated with the use of trastuzumab. Design and conduct a practical approach to managing patients with trastuzumab-associated cardiotoxicity. This article is available for continuing medical education credit at CME.TheOncologist.com.
Constrictive Pericarditis
Sengupta, Partho P. , Eleid, Mackram F. , Khandheria, Bijoy K.

Mayo Clinic

Circulation Journal | September 25, 2008 | Volume: 72 | Issue: 10 | Pages: 1555-1562

10.1253/circj.cj-08-0654 | PMID 18762706 Get It

Prostate Specific Antigen Kinetics in the Management of Prostate Cancer
Sengupta, Shomik , Amling, Christopher L. , D’Amico, Anthony V. , Blute, Michael L.

Mayo Clinic

Journal of Urology | January 28, 2008 | Volume: 179 | Issue: 3 | Pages: 821-826

10.1016/j.juro.2007.10.023 | PMID 18221963 Get It

Tumor-Infiltrating Foxp3−CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma
Siddiqui, Sameer , Frigola, Xavier, Bonne-Année, Sandra, Mercader, Maria, Kuntz, Susan M., Krambeck, Amy E. , Sengupta, Shomik , Cheville, John C. , Lohse, Christine M. , Krco, Christopher J., Webster, W. Scott, Leibovich, Bradley C. , Blute, Michael L., Knutson, Keith L. , Kwon, Eugene D., Dong, Haidong , Knutson, Keith L.

Mayo Clinic

Clinical Cancer Research | April 2, 2007 | Volume: 13 | Issue: 7 | Pages: 2075-2081

10.1158/1078-0432.ccr-06-2139 | PMID 17404089 Get It

AbstractPurpose: Regulatory T cells (Tregs) have been implicated as inhibitors of antitumoral immunity, and evidence suggests that elimination of Tregs may augment natural and pharmacologic immunity. We tested for the presence of putative Tregs within renal cell carcinoma (RCC) tumors.Experimental Design: We identified 170 patients who underwent radical or partial nephrectomy for clear cell RCC between 2000 and 2002. Specimens were stained with anti-CD4, anti-CD25, and anti-Foxp3 antibodies and examined using confocal microscopy. Associations of CD4+CD25+Foxp3− and CD4+CD25+Foxp3+ T cells with death from RCC were evaluated using Cox proportional hazards regression models.Results: At last follow-up, 46 of 170 patients had died; of these, 37 died from RCC at a median of 1.4 years following nephrectomy (range, 0-4.4). Among the 124 remaining patients, median follow-up was 3.7 years (range, 0-5.7). Forty-three (25.3%) tumors harbored CD4+CD25+Foxp3+ T cells. The presence of Foxp3+ T cells was not significantly associated with RCC death univariately. One hundred forty-three (84.1%) tumors harbored CD4+CD25+Foxp3− T cells. The indicator for ≥10% CD4+CD25+Foxp3− T cells was significantly associated with RCC death univariately [risk ratio (RR), 2.60; 95% confidence interval (95% CI), 1.35-4.98; P = 0.004], after adjusting for tumor B7-H1 expression (RR, 2.53; 95% CI, 1.32-4.85; P = 0.005) and lymphocytic infiltration (RR, 2.53; 95% CI, 1.32-4.87; P = 0.005).Conclusions: Increased presence of CD4+CD25+Foxp3+ T cells was not significantly associated with RCC death. In contrast, CD4+CD25+Foxp3− T cells, which may represent a unique set of Tregs or activated helper T cells, was significantly associated with outcome.
Editorial Comments
Sengupta, Shomik , Zincke, Horst

Mayo Clinic

Journal of Urology | October 26, 2006 | Volume: 176 | Issue: 5 | Pages: 1988-1989

10.1016/j.juro.2006.07.189 Get It

Impact of Familial and Hereditary Prostate Cancer on Cancer Specific Survival After Radical Retropubic Prostatectomy
Siddiqui, Sameer , Sengupta, Shomik , Slezak, Jeffrey M., Bergstralh, Eric J., Zincke, Horst, Blute, Michael L.

Mayo Clinic

Journal of Urology | August 9, 2006 | Volume: 176 | Issue: 3 | Pages: 1118-1121

10.1016/j.juro.2006.04.077 | PMID 16890705 Get It

Detectable Prostate Specific Antigen Between 60 and 120 Days Following Radical Prostatectomy for Prostate Cancer: Natural History and Prognostic Significance
Sengupta, Shomik , Christensen, C. M., Zincke, Horst, Slezak, Jeffrey M., Leibovich, Bradley C. , Bergstralh, Eric J., Myers, Robert P., Blute, Michael L.

Mayo Clinic

Journal of Urology | June 29, 2006 | Volume: 176 | Issue: 2 | Pages: 559-563

10.1016/j.juro.2006.03.086 | PMID 16813889 Get It

Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts Survival
Sengupta, Shomik , Blute, Michael L., Bagniewski, Stephanie M., Myers, Robert P., Bergstralh, Eric J., Leibovich, Bradley C. , Zincke, Horst

Mayo Clinic

Journal of Urology | April 6, 2006 | Volume: 175 | Issue: 5 | Pages: 1684-1690

10.1016/s0022-5347(05)00978-x | PMID 16600730 Get It

Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up
Thompson, R. Houston, Kuntz, Susan M., Leibovich, Bradley C. , Dong, Haidong , Lohse, Christine M. , Webster, W. Scott, Sengupta, Shomik , Frank, Igor, Parker, Alexander S. , Zincke, Horst, Blute, Michael L., Sebo, Thomas J., Cheville, John C. , Kwon, Eugene D., Dong, Haidong

Mayo Clinic

Cancer Research | April 3, 2006 | Volume: 66 | Issue: 7 | Pages: 3381-3385

10.1158/0008-5472.can-05-4303 | PMID 16585157 Get It

Abstract B7-H1 participates in T-cell costimulation functioning as a negative regulator of immunity. Recent observations suggest that B7-H1 is expressed by renal cell carcinoma (RCC) tumor cells and is associated with poor prognosis. However, outcome analyses have been restricted to patients with fresh-frozen tissue and limited follow-up. We report the clinical effect of B7-H1 in RCC patients with a median of 10 years of follow-up. Between 1990 and 1994, 306 patients underwent nephrectomy for clear cell RCC and had paraffin tissue available for review. We did immunohistochemistry with anti-B7-H1 and conducted outcome analyses. Among the 306 patients, 73 (23.9%) harbored tumors with B7-H1 expression. Patients with tumor B7-H1 were at a significantly increased risk of both death from RCC [risk ratio (RR), 3.92; P < 0.001] and overall mortality (RR, 2.37; P < 0.001). The 5-year cancer-specific survival rates were 41.9% and 82.9% for patients with and without tumor B7-H1, respectively. In a multivariate model, tumor B7-H1 remained associated with cancer-specific death even after adjusting for tumor-node-metastasis stage, grade, and performance status (RR, 2.00; P = 0.003). In the subset of 268 patients with localized RCC, tumor B7-H1 was significantly associated with metastatic cancer progression (RR, 3.46; P < 0.001) and death from RCC (RR, 4.13; P < 0.001) even after adjusting for stage, grade, and performance status (RR, 1.78, P = 0.036). RCC patients with tumor B7-H1 are at significant risk of rapid cancer progression and accelerated rates of mortality. B7-H1 may function as a key determinant in RCC, abrogating immune responses directed against this immunogenic tumor. (Cancer Res 2006; 66(7): 3381-5)
Impact of Patient Age at Treatment on Outcome Following Radical Retropubic Prostatectomy for Prostate Cancer
Siddiqui, Sameer , Sengupta, Shomik , Slezak, Jeffrey M., Bergstralh, Eric J., Leibovich, Bradley C. , Myers, Robert P., Zincke, Horst, Blute, Michael L.

Mayo Clinic

Journal of Urology | February 10, 2006 | Volume: 175 | Issue: 3 | Pages: 952-957

10.1016/s0022-5347(05)00339-3 | PMID 16469591 Get It